A new study estimates that nearly 1 in 4 people with P. falciparum malaria in Africa are at risk of receiving too low a dose of artemisinin combination therapies (ACTs), increasing the chance of treatment failure and the risk that malarial parasites develop resistance to the drug they were exposed t...

A meta-analysis of nearly 30,000 patients suggests that a post-treatment follow-up duration of longer than 6-months may be needed to identify visceral leishmaniasis relapses.

The WorldWide Antimalarial Research Network’s (WWARN) website has a new home and now sits within the Infectious Diseases Data Observatory portfolio of research themes.

Professor Paul Newton, head of IDDO’s Medicine Quality Research Group has received an ‘Excellent Supervisor’ award.

IDDO and WWARN are delighted to be taking part in this year’s 13th European Congress on Tropical Medicine and International Health, (ECTMIH), and will be sharing our latest research across visceral leishmaniasis, malaria, medicine quality and lymphatic filariasis.

IDDO is part of a coalition of over 900 scientists calling for a fairer investment in infectious disease research in low resource areas

The WWARN Vivax adherence study group-led meta-analysis finds that poor adherence to primaquine treatment regimens increased recurrence by 2.3-fold.

A collaborative study by researchers from the Institut de Recherche en Sciences de La Santé of Nanoro (IRRS-Nanoro) in Burkina Faso and IDDO/WWARN has found that giving young children vitamin and lipid supplements at the same time as seasonal malaria chemoprevention reduces the incidence of severe ...

An international consortium of multidisciplinary researchers and specialists has developed a new method to counter the problem of COVID-19 vaccine falsification.

Professor Philippe Guérin, IDDO and WWARN’s Director, has been awarded the Bailey K. Ashford Medal for his “distinguished” work in tropical medicine.

Join IDDO and WWARN’s researchers at this year’s ASTMH - the 72nd annual meeting in Chicago, USA, where we will be presenting on Visceral Leishmaniasis, malaria, and medicine quality across symposia, oral presentations and posters.

Analysis of data from more than 6,800 patients located across 16 countries has supported the need to increase the dose of the antimalarial drug, primaquine, in malaria endemic countries.

A new viewpoint calling for the standardisation of antibiotics appearance and better information around usage, has been published in The Lancet Global Health.

A research letter published in The Lancet has emphasised the critical need for equity in the allocation of research funding, especially in the context of epidemic response efforts. The letter, ‘Pandemics move faster than funders’ is authored by the members of the COVID-19 Clinical Research Coalition...

The second annual FORESFA meeting, held in Edinburgh, stimulated discussion on forensic investigations of falsified medicines and engagement with potential implementers.

A new WWARN study, which looked at the variability in white blood cell (WBC) count in patients with uncomplicated malaria, found that using the assumed value of WBC in the calculation of parasite density led to a significant underestimation of parasite count for children and potentially sub-optimal ...

The Medicine Quality Research Group took part in an in-person workshop on ‘good laboratory practices’ to support capacity-building and networking for medicines regulators from different countries.

A global collaboration of the visceral leishmaniasis (VL) community has developed freely available, annotated case report forms (CRF) to accelerate research both into uncomplicated VL and specifically for patients with HIV-VL co-infection. The CRFs allow the collection of research-related data in a ...

While 17 countries have now achieved trachoma elimination status, there is still work to be done, with trachoma responsible for the blindness or visual impairment of about 1.9 million people worldwide. Collaborators are being invited to join a new research project aimed at assessing the drivers for ...